Impact of Nutrition or FDA-Approved Medicine Repurposing on Metabolic Syndrome and Diabetic Complications-Reference-Cited by-同舟云学术

Impact of Nutrition or FDA-Approved Medicine Repurposing on Metabolic Syndrome and Diabetic Complications

Published:2023-05-29 Issue:11 Volume:15 Page:2515
ISSN:2072-6643
Container-title:Nutrients
language:en
Short-container-title:Nutrients

Author:

Cai Lu¹^ORCID

Affiliation:

1. Pediatric Research Institute, Departments of Pediatrics, Radiation Oncology, Pharmacology and Toxicology, The University of Louisville School of Medicine, and Wendy Novak Diabetes Institute, Norton HealthCare, Louisville, KY 40202, USA

Abstract

Both obesity and diabetes are global health threats due to their high risk of developing different complications [...]

Funder

National Institute of Environmental Health Sciences

Publisher

MDPI AG

Subject

Food Science,Nutrition and Dietetics

Link

https://www.mdpi.com/2072-6643/15/11/2515/pdf

Reference10 articles.

1. Lu, X., Huang, R., Li, S., Fang, A., Chen, Y., Chen, S., Wang, F., Lin, X., Liu, Z., and Zhu, H. (2022). Associations between Serum Betaine, Methyl-Metabolizing Genetic Polymorphisms and Risk of Incident Type 2 Diabetes: A Prospective Cohort Study in Community-Dwelling Chinese Adults. Nutrients, 14.

2. C677T and A1298C methylenetetrahydrofolate reductase polymorphisms and breast cancer susceptibility among Latinos: A meta-analysis;Porchia;Breast Cancer,2019

3. The association between MTHFR polymorphisms and cervical cancer risk: A system review and meta analysis;Yi;Arch. Gynecol. Obstet.,2016

4. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against the insulin resistance and hepatic steatosis in db/db mice;Yuan;Eur. J. Pharmacol.,2016

5. Chen, Y., Li, J., Zhang, M., Yang, W., Qin, W., Zheng, Q., Chu, Y., Wu, Y., Wu, D., and Yuan, X. (2022). 11β-HSD1 Inhibitor Alleviates Non-Alcoholic Fatty Liver Disease by Activating the AMPK/SIRT1 Signaling Pathway. Nutrients, 14.